Collateral vessels provide a mechanism to protect against adverse outcomes associated with atherosclerosis. 1-3 For people with lower extremity peripheral artery disease (PAD), collateral vessels are a natural bypass system, protect against critical limb ischemia, and may reduce ischemia-related leg symptoms. 3 However, collateral vessels do not restore perfusion to normal. 2 Whether collateral vessels protect against functional decline in people with PAD is unknown.
Introduction
functional decline, compared to people with PAD who have less plaque burden and/or more numerous collateral vessels. We also studied whether a smaller SFA lumen area combined with less numerous collateral vessels was associated with faster functional decline. We hypothesized that the combination of greater plaque burden (or smaller lumen area) combined with less numerous collateral vessels would be associated with faster functional decline in people with PAD. In separate analyses, we also studied the associations of collateral vessel number, SFA plaque burden, and SFA lumen area, respectively, to rates of functional decline in PAD.
Methods

Subjects
Participants were enrolled in the Walking and Leg Circulation Study (WALCS III) cohort, a longitudinal observational study relating baseline magnetic resonance imaging (MRI)-measured plaque severity to functional impairment and functional decline among individuals with PAD. Recruitment and data collection methods have been reported. 7 Participants were identified from among consecutive PAD patients in non-invasive vascular laboratories at Northwestern Memorial Hospital and three other Chicagoarea medical centers. Participants were also identified from among lists of consecutive PAD patients in vascular surgery, cardiology, endocrinology, general medicine, and geriatric practices at Northwestern and in the vascular surgery practice at the Jesse Brown VA. Some PAD participants were identified from among consecutive men and women aged 70 years and older in a general medical practice who were screened with the ABI and found to have an ABI <1.00. 7 The protocol was Institutional Review Board-approved by all participating sites. Participants gave written informed consent. Participants completed a baseline visit and were asked to return for two annual follow-up visits.
Inclusion criteria
The inclusion criterion was an ABI <1.00. This inclusion criterion was selected because truly normal ABI values are 1.10-1.40 [8] [9] [10] and because including participants with an ABI <1.00 ensured a broad range of severity of lower extremity atherosclerosis.
Exclusion criteria
Potential participants with dementia and those with a minimental status examination score <23 11 were excluded. Nursing home residents, wheelchair-bound patients, and patients with foot or leg amputations were excluded because of severely impaired functioning at baseline. Non-Englishspeaking patients were excluded because investigators were not fluent in non-English languages. We excluded potential participants who required oxygen therapy, had contraindications to MRI, stopped the 6-minute walk test due to shortness of breath, had undergone recent major surgery, or had severe knee osteoarthritis. Severe arthritis was defined as a radiograph-measured osteoarthritis Kellgren-Lawrence (K/L) score of four among participants who reported pain in or around their knee(s) on most days. 12 
ABI measurement
After participants had rested supine for 5 minutes, a handheld Doppler probe (Pocket-Dop II; Nicolet Vascular, Golden, CO, USA) was used to measure systolic pressures in this order: right brachial, dorsalis pedis, and posterior tibial arteries, and left dorsalis pedis, posterior tibial, and brachial arteries. Pressures were repeated in reverse order. The ABI was calculated by dividing average pressures in each leg by the average of the four brachial pressures. 13 Average brachial pressures in the arm with the highest pressure were used when one brachial pressure was higher than the opposite brachial pressure in both measurement sets, and the two brachial pressures differed by 10 or more mmHg in at least one measurement set, since in such cases subclavian stenosis was possible. 14 Data from undetectable or incompressible dorsalis pedis and posterior tibial arteries were excluded from the ABI calculation.
Magnetic resonance imaging
We imaged the SFA because it is the most common site of lower extremity atherosclerosis 15 and because it supplies calf muscle, which is typically symptomatic in PAD. The leg with the lowest ABI was imaged. If the leg with the lowest ABI had an SFA stent, the opposite leg was imaged. MRI data were obtained with a 1.5 Tesla (Siemens Medical Solutions, Erlangen, Germany) platform using four-element phased-array surface coils. Twelve consecutive 2.5 mm cross-sectional images were obtained, moving distally from the most proximal point of the SFA using the common femoral artery bifurcation as a landmark. We used 2-dimensional bright blood time-of-flight and proton-density weighted images. Fat suppression was applied in blackblood sequences to improve image quality.
Two physician reviewers used CASCADE software (Seattle, WA, USA) to trace the outer boundary and the lumen of each SFA cross-sectional image. CASCADE software quantified the plaque area based on the tracings. Plaque measurements were normalized for artery size by dividing the measured maximum plaque area by the median of the outer wall area. 7 To normalize the lumen area measures, the minimum lumen area was divided by the outer wall area at each site. Images for each participant were assigned to one primary reviewer, and arterial tracings were reviewed by the second reviewer to ensure accuracy. A 6% subsample of participants returned for a second day for test re-test reliability assessments of MRI measurements. The coefficient of variation percent values for these test re-test reliability assessments were 8.9 for maximum plaque area and 12.9 for minimum percent lumen area.
Magnetic resonance angiography
A 1.5 T Siemens Espree (Siemens Medical Solutions, Erlangen, Germany) MRI scanner was employed for magnetic resonance angiography (MRA) image acquisition using a 12-channel surface array coil (Siemens Medical Solutions). Dynamic MRA images from one station, the groin to the knee, were acquired from both legs, including the common femoral artery, the profunda femoris, the SFA, and the popliteal artery using the TWIST (Time resolved angiography With Interleaved Stochastic Trajectories) pulse sequence. 6 Parallel imaging with generalized autocalibrating partially parallel acquisitions (GRAPPA) image reconstruction provided a twofold increase in frame rate. Following a three-plane localizer image, the TWIST sequence was applied in the coronal orientation. A 
MRA image analysis
A single radiologist, blinded to all other participant characteristics, read all MRA images on a workstation using established methods (GE Healthcare, Milwaukee, WI, USA). 16, 17 Based on prior work, 6,18 a collateral vessel was defined based on a subjective impression of the presence of a collateral on an image. We also required that the collateral be visible throughout its length on the image, in order for it to be counted. The median number of collateral vessels per participant in our cohort was 5.9. Thus, we categorized participants according to whether they had 0-5 collateral vessels versus ≥6 collateral vessels.
Functional measures
Functional assessments were obtained at baseline and annually for up to two follow-up visits.
Six-minute walk. After standardized instructions by a certified health interviewer, participants walk up and down a 100-foot hallway for 6 minutes. 4, 5 Participants are advised to cover as much ground as possible during the 6 minutes. The health interviewer walks slightly behind the participant. The distance walked at the end of 6 minutes is recorded.
Four-meter walking velocity. Walking velocity was measured with a 4-meter walk performed at 'usual' and 'fastest' pace, based on previous study. 4, 7, 19 For the usual-paced walk, participants are instructed to walk at their usual pace, 'as if they are walking down the street to go to the store'. For the fastest-paced walk, participants are advised to walk at their fastest pace. Each walk is performed twice. The faster walk in each pair is used in analyses. 4, 7, 19 Comorbidities. Algorithms developed for the Women's Health and Aging Study and the Cardiovascular Health Study were used to document comorbidities. 20 These algorithms combine data from patient report, physical examination, medical record review, medications, laboratory values, and a primary care physician questionnaire. 20 The comorbidities assessed were angina, diabetes mellitus, myocardial infarction, stroke, heart failure, pulmonary disease, cancer, spinal stenosis, and disk disease. Criteria from the American College of Rheumatology were used to diagnose knee and hip osteoarthritis. 12, 21 Other measures. Height and weight were measured at the study visit. Body mass index (BMI) was calculated as weight (kg)/(height (m)) 2 . Cigarette smoking was measured with self-report.
Statistical analyses
The following groups were defined for specific combinations of plaque area and number of collateral vessels: Group 1 (best): maximum plaque area < median and collateral vessel number ≥6 (i.e. least plaque combined with most numerous collateral vessel number); Group 2: maximum plaque area < median and collateral vessel number < 6; Group 3: maximum plaque area > median and collateral vessel number ≥6; Group 4 (worst): maximum plaque area > median and collateral vessel number <6 (i.e. greatest plaque combined with least numerous collateral vessel number). Similar groups were defined for the combination of minimum lumen area with collateral vessel number ≥6 vs <6 (Table 1) .
Differences in continuous and dichotomous variables were compared across the four groups defined for maximum plaque area and minimum lumen area, respectively, using analyses of variance and chi-squared tests, respectively. Average annual declines in each functional measure were compared across the four groups defined in Table  1 using analyses of covariance, adjusting for age, sex, race, prior year performance, smoking, BMI, and comorbidities. For each group, pairwise comparisons were made between Group 1 (best) and each remaining group. Analyses were repeated with additional adjustment for ABI. Associations of baseline plaque and baseline collateral measures, respectively, with average annual decline in each functional performance measure were also determined adjusting for age, sex, race, BMI, smoking, and comorbidities. Table 2) . Participants with the combination of high plaque area and few collateral vessels (Group 4) had lower BMI values than those with low plaque area and more numerous collateral vessels (Group 1).
Significant differences in rates of decline in usual-paced 4-meter walking velocity were observed across Groups 1-4 for plaque area and for lumen area, adjusting for age, sex, race, prior year performance, comorbidities, BMI, and smoking ( Figure 1 ). Participants with high plaque area combined with less numerous collateral vessels (Group 4) had faster decline in usual-paced 4-meter walking velocity, compared to participants with low plaque area combined with more numerous collateral vessels (Group 1) (p<0.001) (Figure 1) . Similarly, participants with the smallest lumen area combined with less numerous collateral vessels (Group 4) had faster decline in usual-paced 4-meter walking velocity, compared to participants with the largest lumen area combined with more numerous collateral vessels (Group 1) (p<0.001) (Figure 1 ). Results were not meaningfully changed when analyses were repeated with additional adjustment for the ABI (Figure 1 ). Similar associations of Groups 1-4 were observed for decline in the fastest-paced 4-meter walking velocity for both maximum plaque area and minimum lumen area, respectively ( Figure 2 ). Again, results were not substantially changed even after additional adjustment for the ABI (Figure 2 ). There were no significant associations of Groups 1-4 with rates of decline in 6-minute walk performance (Figure 3 ). There were no associations of plaque area alone or lumen area alone with decline in usual or fastest-paced 4-meter walking velocity or 6-minute walk performance, adjusting for age, sex, race, comorbidities, smoking, BMI, and prior year performance (Table 3 ). However, when collateral vessels were categorized according to whether the number of collaterals was equal to or more than the median (≥6 collateral vessels), versus less than the median (<6 collateral vessels), those with fewer collateral vessels had faster decline in the usual and fastest-paced walking velocity, adjusting for age, sex, race, comorbidities, smoking, BMI, and prior year performance (Table 3 ).
Discussion
Among 226 people with an ABI <1.00, the combination of greater plaque burden with less numerous collateral vessels was associated with a significantly faster annual decline in usual-paced and fastest-paced 4-meter walking velocity. Similarly, smaller lumen area combined with less numerous collateral vessels was associated with a faster decline in usual-paced and fastest-paced walking velocity. Differences in rates of decline between Group 1 and Group 4 for plaque area and for lumen area were consistent with a clinically meaningful decline in walking velocity. 22 Specifically, previous study demonstrates that a small meaningful difference in walking velocity is a change of 0.50 meters/second because this magnitude of difference in decline in walking velocity has been linked with changes in mobility disability. 22 Thus, differences in change in 4-meter walking velocity between Groups 1 and 4 were consistent with small meaningful differences. In contrast, the combination of plaque and collateral characteristics, defined by Groups 1-4, was not associated with the degree of decline in 6-minute walk performance. Usual and fastest-paced 4-meter walking velocity are distinct measures as compared to the 6-minute walk, since 4-meter walking velocity relies more on Type 2 muscle fiber performance, while the 6-minute walk measures walking endurance and relies on Type 1 muscle fibers. Our results suggest that characteristics associated with a decline in walking endurance measures, such as the 6-minute walk, may differ from those associated with a decline in shorter walking performance measures, such as the 4-meter walking velocity. For example, calf muscle density, mitochondrial metabolism, walking efficiency, and cardiopulmonary fitness may be more important determinants of decline in the 6-minute walk than superficial femoral artery plaque burden or collateral vessels. 23, 24 Prior work shows that usual-paced and fastest-paced 4-meter walking velocity predict all-cause mortality, cardiovascular disease mortality, and mobility loss in people with PAD. 25, 26 Thus, usual and fastestpaced 4-meter walking velocity are important outcomes in people with PAD. Collaterals develop from pre-existing arterioles that enlarge in response to sheer stress forces precipitated by arterial stenosis and activation of mechanosensors. Animal evidence suggests that following arterial occlusion, vessels first increase rapidly in number and later enlarge in diameter. 27 These collateral vessels serve as a natural bypass system and are thought to protect against critical limb ischemia. Significant resources have been invested in identifying interventions to increase collateral vessel number or size to improve walking performance in people with PAD. 28, 29 To our knowledge, no prior studies have assessed associations of plaque burden, collateral vessels, or their combination with functional decline in people with PAD. We did not find consistent, statistically significant associations of plaque burden or lumen area alone with rates of decline in any walking performance measure in people with PAD. However, PAD participants with less than the median number of collateral vessels had significantly faster decline in usual and fastest-paced 4-meter walking velocity than those with greater numbers of collateral vessels. The combination of greatest plaque burden or smallest lumen area PAD with less numerous collaterals was associated with faster functional decline compared to other PAD participants. Prior clinical trials using pharmacologic therapy to increase angiogenesis and arteriogenesis in people with PAD have not demonstrated that these medications can improve functional performance in PAD. 30, 31 Our findings suggest that these therapies may be most effective in PAD patients with the most severe lower extremity atherosclerosis. Our findings also suggest that the combination of greatest lower extremity plaque burden or smallest lumen area combined with fewer collateral vessels is associated with a faster decline in walking velocity but not walking endurance. Together, this information may be helpful for future trials attempting to improve walking performance by increasing angiogenesis in people with PAD.
This study has limitations. First, we imaged a short segment of the SFA. We did not image atherosclerotic plaque in the aorto-iliac or femoro-popliteal arterial segments. Associations of plaque burden and lumen area with functional decline may have been more robust if we had imaged additional segments of the lower extremity arterial tree. Second, our collateral vessel data are limited to those who were eligible for and consented to MRA. Our findings regarding collateral vessels may not be generalizable to individuals who did not undergo MRA. Third, MRA has lower spatial resolution than computed tomographic angiography or digital subtraction angiography. Some collateral vessels may be too small for identification on MRA. 32 Fourth, we did not measure step length or cadence during the 4-meter walk or 6-minute walk. Fifth, we cannot rule out the possibility that severity of leg symptoms, exercise behavior, physical activity, or other unmeasured confounders may explain associations reported here. However, additionally adjusting our analyses for leg symptoms and physical activity did not significantly alter our findings.
In conclusion, PAD participants with greater plaque burden or smaller lumen area in the superficial femoral artery combined with less numerous collateral vessels or lower collateral grade have faster rates of decline in usual and fastest-paced 4-meter walking velocity. Further study is needed to identify whether interventions that simultaneously reduce plaque burden and increase collateral vessel number and size can prevent functional decline or improve functional performance in people with PAD.
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